MX2016011675A - Compuestos dirigidos a las celulas madre de cancer. - Google Patents

Compuestos dirigidos a las celulas madre de cancer.

Info

Publication number
MX2016011675A
MX2016011675A MX2016011675A MX2016011675A MX2016011675A MX 2016011675 A MX2016011675 A MX 2016011675A MX 2016011675 A MX2016011675 A MX 2016011675A MX 2016011675 A MX2016011675 A MX 2016011675A MX 2016011675 A MX2016011675 A MX 2016011675A
Authority
MX
Mexico
Prior art keywords
cancer stem
stem cell
cell targeting
targeting compounds
stem cells
Prior art date
Application number
MX2016011675A
Other languages
English (en)
Inventor
Srivastava Sangeeta
Athavale Maithili
Shukre Kedar
More Gayatri
Original Assignee
Godavari Biorefineries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Godavari Biorefineries Ltd filed Critical Godavari Biorefineries Ltd
Publication of MX2016011675A publication Critical patent/MX2016011675A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención provee compuestos de fórmula (I), composiciones y usos de los mismos y métodos para inhibir la proliferación de las células madre de cáncer o para destruirlas, que incluye matarlas, o para inducir apoptosis en las células madre de cáncer. Dentro del alcance de tales compuestos, composiciones, sus usos y métodos se incluye en donde la proliferación de células madre de cáncer es erradicada o inhibida selectivamente.
MX2016011675A 2014-03-11 2015-03-11 Compuestos dirigidos a las celulas madre de cancer. MX2016011675A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN815MU2014 IN2014MU00815A (es) 2014-03-11 2015-03-11
PCT/IN2015/050020 WO2015136557A2 (en) 2014-03-11 2015-03-11 Cancer stem cell targeting compounds

Publications (1)

Publication Number Publication Date
MX2016011675A true MX2016011675A (es) 2016-12-14

Family

ID=54072550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011675A MX2016011675A (es) 2014-03-11 2015-03-11 Compuestos dirigidos a las celulas madre de cancer.

Country Status (9)

Country Link
US (1) US20180169100A1 (es)
EP (1) EP3116867A4 (es)
JP (1) JP2017507969A (es)
AU (1) AU2015228386A1 (es)
CA (1) CA2941703A1 (es)
IL (1) IL247723A0 (es)
IN (1) IN2014MU00815A (es)
MX (1) MX2016011675A (es)
WO (1) WO2015136557A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1675861B1 (en) * 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US8993552B2 (en) * 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia

Also Published As

Publication number Publication date
EP3116867A2 (en) 2017-01-18
WO2015136557A2 (en) 2015-09-17
CA2941703A1 (en) 2015-09-17
IN2014MU00815A (es) 2015-09-25
WO2015136557A3 (en) 2015-11-12
JP2017507969A (ja) 2017-03-23
AU2015228386A1 (en) 2016-09-22
US20180169100A1 (en) 2018-06-21
EP3116867A4 (en) 2017-10-18
IL247723A0 (en) 2016-11-30
WO2015136557A9 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
PH12017500660A1 (en) Novel compositions, uses and methods for making them
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
CL2016002394A1 (es) Derivados de quinolina como inhibidores de smo
PH12015502028A1 (en) Ido inhibitors
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
TW201613966A (en) SynTac polypeptides and uses thereof
PH12015501150A1 (en) Compounds and their methods of use
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201691916A1 (ru) Биарильные ингибиторы киназы
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
IN2015DN01197A (es)
IN2015DN01161A (es)
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2018003301A (es) Inhibidores de pcna.